Рецепт. 2021; : 114-121
Постковидный синдром
https://doi.org/10.34883/PI.2021.24.1.010Аннотация
Представлен обзор по коронавирусной инфекции с описанием клинических проявлений и лечения постковидного синдрома. Сделано предположение о возможности применения кавинтона ввиду его широкого спектра фармакологического действия при постковидном синдроме.
Список литературы
1. Solovieva N., Manarova E., Kichun I. (2020) Koronavirusny`j sindrom: profilaktika psikhotravmy` COVID-19 [Coronavirus syndrome: prevention of psychotrauma COVID-19]. Russian medical journal, no 6, pp. 25–28.
2. Anaczkaya L. (2020) Taktika lecheniya nevrologicheskikh zabolevanij v period pandemii. [Treatment tactics for neurological diseases during the pandemic]. Medical bulletin, no 20, pp. 4–5.
3. Vorobiev P. (2020) Postkovidny`j sindrom [Postcovid syndrome]. Available at: //www.youtube.com
4. Fedin A. (2020) Ostry`e insul`ty`, assocziirovanny`e s COVID-19 [Acute strokes associated with COVID-19]. Neuronews, no 7–8, pp. 2–4.
5. Reva G. (2020) Erythrocytes as a target of SARS COV-2 in pathogenesis of COVID-19. Archive Euromedica, no 3, pp. 23–24.
6. Adaskevich V. (2020) Dermatologicheskie proyavleniya u paczientov s COViD-19 [Dermatological manifestations in COViD-19 patients]. Medical bulletin, no 20, pp. 14–15.
7. Grigorieva O. (2020) Virus vnutri [The virus is inside]. Medical bulletin, no 20, pp. 12–13.
8. Grigorieva O. (2020) Dolgij-dolgij COVID [Long-long COVID]. Medical bulletin, no 50, p. 24.
9. Imsheneczkaya T. (2020) Oftal`mologicheskaya pomoshh` v usloviyakh COViD-19 [Ophthalmic care in COViD-19 conditions]. Medical bulletin,no 20, p. 5.
10. Martusevich N. (2020) Revmaticheskie zabolevaniya i COViD-19 v voprosakh i otvetakh [Rheumatic diseases and COViD-19 in questions and answers]. Medical bulletin, no 20, pp. 10–11.
11. Mitkovskaya N. (2020) Serdechno-sosudisty`e zabolevaniya v kontekste pandemii COVID-19 [Cardiovascular disease in the context of the COVID-19 pandemic]. Medical bulletin, no 26, pp. 6–7.
12. Fedin A. (2020) Nevrologicheskaya klinicheskaya patologiya, assocziirovannaya s COVID-19 [Neurological clinical pathology associated with COVID-19]. Neuronews, no 4, pp. 2–5.
13. Vorobiev P. (2020) Antitromboticheskaya profilaktika u pozhily`kh bol`ny`kh s Covid-19 v ostroj faze i pri postkovidnom sindrome [Antithrombotic prophylaxis in elderly patients with Covid-19 in the acute phase and postcovid syndrome]. Paper was presented at the “An elderly patient. The quality of life” International scientific and practical conference, 30.09–01.10.2020, Moscow.
14. Dennis A., Wamil M., Kapur S. (2020) Multiorgan impairment in low risk individuals with long Covid. //doi:https://doi.org/101101/2020 10.14.20212555
15. Menni C.Sudre C.H., Steves C.J. (2020) Widespread smell testing for COVID-19 has limited application - Authors reply. The Lancet, no 3, pp. 35–40.
16. Grunfi F., CorasollaCaregari V., Veras F.P. (2020) SARS-COV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. medRxiv.10.09.20 207464
17. Jeon K.-I., Xu.X, Aizawa T. (2010) Vinpocetine inhibits NF-kappaB- dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl.Acad.Sci. USA, no 21, pp. 9795–9800.
18. Kozlovskij V., Fisenko V. (2014) Kavinton (vinpoczetin): farmakologicheskie e`ffekty`, princzipy` dejstviya i primeneniya v klinicheskoj praktike[Cavinton (vinpocetine): pharmacological effects, principles of action and application in clinical practice]. Moscow: ОАО «CONTI-PRINT.
19. Petrov V., Fagard V.R., Lijenen P. (1998) Human erythrocytes contain Ca, calmodulin-dependent cyclic nucleotide phosphodiesterase which is involved in the hydrolysis of cGMP. Meth.Find.Exp.Clin.Pharmacol., no 5, pp. 387–393.
20. Hayakawa M. (1992) Effect of vinpocetine on red blood cell deformability in stroke patients. Arzneimit.-Forsch., no 4, pp. 425–427.
21. Muraviev A., Koshelev V., Fadyukova O. (2011) Rol` adenilatcziklaznoj sistemy` e`ritroczitov v izmenenii mikroreologicheskikh svojstv ikh membran [The role of the erythrocyte adenylate cyclase system in changing the microrheological properties of their membranes]. Biological Membranes: Journal of Membrane and Cell Biology, no 3, pp. 174–180.
22. Veselskij I., Sanik A. (1991) Mikroczirkulyacziya, reologicheskie svojstva krovi i ikh korrekcziya pri ishemicheskikh narusheniyakh mozgovogo krovoobrashheniya [Microcirculation, rheological properties of blood and their correction in ischemic disorders of cerebral circulation]. Journal of Neuropathology and Psychiatry. S.S. Korsakov, no 1, pp. 67–70.
23. Kozlovskij V. (2005) Vozmozhnosti primeneniya kavintona (vinpoczetina) v profilaktike porazhenij sosudistoj sistemy` pri arterial`noj gipertenzii [Possibilities of using cavinton (vinpocetine) in the prevention of lesions of the vascular system in arterial hypertension]. Medical panorama, no 7, pp. 26–29.
24. Feher G., Koltai K., Kesmarky G. (2009) Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine, no 2–3, pp. 111–117.
25. Szapary L., Hovath B., Alexy T. (2003) Effect of vinpocetine on the hemo-rheologic parameters in patients with chronic cerebrovascular disease.Orv. Hetil, no 20, pp. 973–978.
26. Szobor A., Klein M. (1992) Examinations of the relative fluidity in cerebrovascular disease patients. Ther.Hung, no 1, pp. 8–11.
27. Tohgi H., Sasaki K., Chiba K. (1990) Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimit. – Forsch., no 6, pp. 640–643.
28. Kryzhanovskij V. (2005) Sovremenny`e aspekty` lecheniya legochnoj gipertenzii i legochnogo serdcza u bol`ny`kh khronicheskoj obstruktivnoj bolezn`yu legkikh [Modern aspects of the treatment of pulmonary hypertension and cor pulmonale in patients with chronic obstructive pulmonary disease]. Medical news, no 11, pp. 33–39.
29. Erdo S., Molnar P., Lackics V. (1996) Vincamine and vincanol are potrnt blockers of volt-age-gated Na channels. Europ.J.Pharmacol., no 1, pp. 69–73.
Recipe. 2021; : 114-121
Postcovid Syndrome
https://doi.org/10.34883/PI.2021.24.1.010Abstract
References
1. Solovieva N., Manarova E., Kichun I. (2020) Koronavirusny`j sindrom: profilaktika psikhotravmy` COVID-19 [Coronavirus syndrome: prevention of psychotrauma COVID-19]. Russian medical journal, no 6, pp. 25–28.
2. Anaczkaya L. (2020) Taktika lecheniya nevrologicheskikh zabolevanij v period pandemii. [Treatment tactics for neurological diseases during the pandemic]. Medical bulletin, no 20, pp. 4–5.
3. Vorobiev P. (2020) Postkovidny`j sindrom [Postcovid syndrome]. Available at: //www.youtube.com
4. Fedin A. (2020) Ostry`e insul`ty`, assocziirovanny`e s COVID-19 [Acute strokes associated with COVID-19]. Neuronews, no 7–8, pp. 2–4.
5. Reva G. (2020) Erythrocytes as a target of SARS COV-2 in pathogenesis of COVID-19. Archive Euromedica, no 3, pp. 23–24.
6. Adaskevich V. (2020) Dermatologicheskie proyavleniya u paczientov s COViD-19 [Dermatological manifestations in COViD-19 patients]. Medical bulletin, no 20, pp. 14–15.
7. Grigorieva O. (2020) Virus vnutri [The virus is inside]. Medical bulletin, no 20, pp. 12–13.
8. Grigorieva O. (2020) Dolgij-dolgij COVID [Long-long COVID]. Medical bulletin, no 50, p. 24.
9. Imsheneczkaya T. (2020) Oftal`mologicheskaya pomoshh` v usloviyakh COViD-19 [Ophthalmic care in COViD-19 conditions]. Medical bulletin,no 20, p. 5.
10. Martusevich N. (2020) Revmaticheskie zabolevaniya i COViD-19 v voprosakh i otvetakh [Rheumatic diseases and COViD-19 in questions and answers]. Medical bulletin, no 20, pp. 10–11.
11. Mitkovskaya N. (2020) Serdechno-sosudisty`e zabolevaniya v kontekste pandemii COVID-19 [Cardiovascular disease in the context of the COVID-19 pandemic]. Medical bulletin, no 26, pp. 6–7.
12. Fedin A. (2020) Nevrologicheskaya klinicheskaya patologiya, assocziirovannaya s COVID-19 [Neurological clinical pathology associated with COVID-19]. Neuronews, no 4, pp. 2–5.
13. Vorobiev P. (2020) Antitromboticheskaya profilaktika u pozhily`kh bol`ny`kh s Covid-19 v ostroj faze i pri postkovidnom sindrome [Antithrombotic prophylaxis in elderly patients with Covid-19 in the acute phase and postcovid syndrome]. Paper was presented at the “An elderly patient. The quality of life” International scientific and practical conference, 30.09–01.10.2020, Moscow.
14. Dennis A., Wamil M., Kapur S. (2020) Multiorgan impairment in low risk individuals with long Covid. //doi:https://doi.org/101101/2020 10.14.20212555
15. Menni C.Sudre C.H., Steves C.J. (2020) Widespread smell testing for COVID-19 has limited application - Authors reply. The Lancet, no 3, pp. 35–40.
16. Grunfi F., CorasollaCaregari V., Veras F.P. (2020) SARS-COV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. medRxiv.10.09.20 207464
17. Jeon K.-I., Xu.X, Aizawa T. (2010) Vinpocetine inhibits NF-kappaB- dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl.Acad.Sci. USA, no 21, pp. 9795–9800.
18. Kozlovskij V., Fisenko V. (2014) Kavinton (vinpoczetin): farmakologicheskie e`ffekty`, princzipy` dejstviya i primeneniya v klinicheskoj praktike[Cavinton (vinpocetine): pharmacological effects, principles of action and application in clinical practice]. Moscow: OAO «CONTI-PRINT.
19. Petrov V., Fagard V.R., Lijenen P. (1998) Human erythrocytes contain Ca, calmodulin-dependent cyclic nucleotide phosphodiesterase which is involved in the hydrolysis of cGMP. Meth.Find.Exp.Clin.Pharmacol., no 5, pp. 387–393.
20. Hayakawa M. (1992) Effect of vinpocetine on red blood cell deformability in stroke patients. Arzneimit.-Forsch., no 4, pp. 425–427.
21. Muraviev A., Koshelev V., Fadyukova O. (2011) Rol` adenilatcziklaznoj sistemy` e`ritroczitov v izmenenii mikroreologicheskikh svojstv ikh membran [The role of the erythrocyte adenylate cyclase system in changing the microrheological properties of their membranes]. Biological Membranes: Journal of Membrane and Cell Biology, no 3, pp. 174–180.
22. Veselskij I., Sanik A. (1991) Mikroczirkulyacziya, reologicheskie svojstva krovi i ikh korrekcziya pri ishemicheskikh narusheniyakh mozgovogo krovoobrashheniya [Microcirculation, rheological properties of blood and their correction in ischemic disorders of cerebral circulation]. Journal of Neuropathology and Psychiatry. S.S. Korsakov, no 1, pp. 67–70.
23. Kozlovskij V. (2005) Vozmozhnosti primeneniya kavintona (vinpoczetina) v profilaktike porazhenij sosudistoj sistemy` pri arterial`noj gipertenzii [Possibilities of using cavinton (vinpocetine) in the prevention of lesions of the vascular system in arterial hypertension]. Medical panorama, no 7, pp. 26–29.
24. Feher G., Koltai K., Kesmarky G. (2009) Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine, no 2–3, pp. 111–117.
25. Szapary L., Hovath B., Alexy T. (2003) Effect of vinpocetine on the hemo-rheologic parameters in patients with chronic cerebrovascular disease.Orv. Hetil, no 20, pp. 973–978.
26. Szobor A., Klein M. (1992) Examinations of the relative fluidity in cerebrovascular disease patients. Ther.Hung, no 1, pp. 8–11.
27. Tohgi H., Sasaki K., Chiba K. (1990) Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimit. – Forsch., no 6, pp. 640–643.
28. Kryzhanovskij V. (2005) Sovremenny`e aspekty` lecheniya legochnoj gipertenzii i legochnogo serdcza u bol`ny`kh khronicheskoj obstruktivnoj bolezn`yu legkikh [Modern aspects of the treatment of pulmonary hypertension and cor pulmonale in patients with chronic obstructive pulmonary disease]. Medical news, no 11, pp. 33–39.
29. Erdo S., Molnar P., Lackics V. (1996) Vincamine and vincanol are potrnt blockers of volt-age-gated Na channels. Europ.J.Pharmacol., no 1, pp. 69–73.
